News briefing: AbbVie selects first target for Dragonfly partnership; Cognito nets BDD for Alzheimer's treatment device
Dragonfly’s partnership with AbbVie is beginning to bear fruit.
AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment, the companies announced Tuesday. AbbVie will gain exclusive worldwide rights to develop and commercialize products directed to this first target, which is also undisclosed, and Dragonfly becomes eligible for future milestones and royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.